Interview with Joan Alvarez, Country Manager, Lundbeck Philippines
You have been involved with Lundbeck since the beginning of its operations in the Philippines. How has the company evolved since you joined seven years ago to be where it…
Address: 6/F Electra House Building, 115-117 Esteban Street, Legaspi Village, Makati City 1200 ,Philippines
Tel: +632 817-3021
Web: http://www.lundbeck.com/global
Lundbeck is a global pharmaceutical company conducting research into, developing, manufacturing, marketing, selling and distributing pharmaceuticals for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy and insomnia.
Lundbeck employs 5,900 people worldwide, 2,100 of whom are based in Denmark. Employees are present in 56 countries, and products are registered in more than 100 countries. The production facilities are located in Italy and Denmark and the research centres in Denmark and the USA.
Lundbeck Philippines started its operations as a representative office in 2003.
Lundbeck markets a number of different pharmaceuticals for the treatment of disorders of the central nervous system (CNS). The most recently launched compounds include: Cipralex/Lexapro (depression), Ebixa (Alzheimer’s disease), Azilect (Parkinson’s disease), Xenazine (chorea associated with Huntington’s disease), Serdolect (schizophrenia), Sabril (epilepsy) and Circadin (sleep disorders).
You have been involved with Lundbeck since the beginning of its operations in the Philippines. How has the company evolved since you joined seven years ago to be where it…
You have been active in the Philippines pharmaceutical sector for more than 30 years. Can you please tell to our readers how this sector has evolved, what the current situation…
See our Cookie Privacy Policy Here
